All Cosmos Bio-Tech Holding Corp (4148) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of All Cosmos Bio-Tech Holding Corp stock TWD 36.41, price TWD 28.80, upside +26.4%, quality 67 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 28.05 TWD – 88.22 TWD · fair‑value band 30.84 TWD – 44.58 TWD · the 28.80 TWD price screens below the 36.41 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow All Cosmos Bio-Tech Holding in your weekly email
Every Wednesday you see whether All Cosmos Bio-Tech Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
All Cosmos Bio-Tech Holding Corporation, through its subsidiaries, manufactures and sells bio-organic and bio-chemical compound fertilizers in Malaysia and internationally. The company offers bio-chemical fertilizers, as well as offers water reutilization services.
Show moreShow less
It also engages in the research and development of microorganisms for waste disposal of oil-palm; and wholesale of probiotics.
In addition, the company offers compound fertilizer; manufactures and sells biological vaccines; and sale of health care, food, cosmetic, skin care, and pharmaceutical products. All Cosmos Bio-Tech Holding Corporation was founded in 1999 and is headquartered in Pasir Gudang, Malaysia.
Stock analysis
All Cosmos Bio-Tech Holding Corp (4148) currently trades at 28.80 TWD, while our model-based Fair Value estimate is 36.41 TWD, implying the stock looks roughly 21% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 50.58 TWD per share, and 20 of the 26 models we run sit above the 28.80 TWD price.
Bear case: the Earnings-Based group reads lowest at 21.30 TWD, and 6 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 30.84 TWD (bear) to 44.58 TWD (bull), the price of 28.80 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
All Cosmos Bio-Tech Holding Corp reported revenue of 2.9B TWD in FY2025 versus 2.2B TWD in FY2021, a compound +7.6%/yr. Reported net income was 153M TWD in FY2025, compounding −6.3%/yr from FY2021.
Key figures
Market cap 2.4B TWD (≈ $72.1M) Micro · P/E ratio 10.4 · P/S ratio 0.61 · EPS (TTM) 2.76 TWD · Dividend yield 3.5% · Net margin 5.9% · Return on equity 7.6% · Return on assets (EBIT) 8.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (medium confidence).
What moves the price
The share trades about 34% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at 4% fair-value upside, at 26%, 4148 screens cheaper than that median.
Fair Value models
Bear30.84 TWDFair Value 36.41 TWDBull44.58 TWD
Price 28.80 TWD · Upside +26.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.51 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+19.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Start year 2020 (pandemic). Over 10 years: +2.7% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +9.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +5.7%
Dividend (yield on the price)3.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 5.7% / −7.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 10%
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 1.28 per share, median 4.50 in 2015 to 2018). It measures the recovery from the trough, not lasting growth.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.4%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −6.9% a year for the price.
Compare All Cosmos Bio-Tech Holding Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 162 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside+26.4% · Top 25%
Profitability
Return on equity (12 months)7.6% · Above median
Return on assets4.9% · Above median
Net margin (12 months)7.9% · Above median
Operating margin (12 months)12.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)33.1% · Top 25%
Dividend yield (12 months)3.5% · Above median
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Agricultural Inputs median · lower = cheaper
P/E (12 months)10.4× · Cheaper than median
P/B0.86× · Cheaper than median
P/S (12 months)1.01× · Pricier than median
Price / free cash flow (fiscal year)15.3× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "All Cosmos Bio-Tech Holding Corp Fair Value". https://www.fairvalue-calculator.com/stock/4148
Frequently asked questions
Is All Cosmos Bio-Tech Holding Corp (4148) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 36.41 TWD versus a price of 28.80 TWD, about +26% upside (undervalued).
What is the fair value of 4148?
Our model-based fair value for All Cosmos Bio-Tech Holding Corp is 36.41 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 28.80 TWD.
What is the quality score of 4148?
All Cosmos Bio-Tech Holding Corp has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for All Cosmos Bio-Tech Holding Corp (4148)?
Our model-based price target is the fair value of 36.41 TWD (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 30.84 TWD, optimistic scenario 44.58 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the All Cosmos Bio-Tech Holding Corp stock forecast for 2026?
Our models put fair value at 36.41 TWD, about +26% upside versus a price of 28.80 TWD (undervalued). Cautious scenario 30.84 TWD, optimistic scenario 44.58 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of All Cosmos Bio-Tech Holding Corp (4148)?
All Cosmos Bio-Tech Holding Corp reported trailing-twelve-month revenue of about 3.2B TWD (latest available figure, as of Nov 9, 2026).
Does All Cosmos Bio-Tech Holding Corp pay a dividend?
All Cosmos Bio-Tech Holding Corp currently shows a dividend yield of 3.47% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of All Cosmos Bio-Tech Holding Corp (4148) and when is the ex-dividend date?
All Cosmos Bio-Tech Holding Corp pays a dividend of 1.00 TWD per share a year, a dividend yield of 3.5%. The last ex-dividend date was Jul 8, 2026. The payout ratio is 36.2% of earnings. Free cash flow covers the dividend 3.11 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into All Cosmos Bio-Tech Holding Corp (4148)?
For today's price to be fair in a discounted-cash-flow model, All Cosmos Bio-Tech Holding Corp would have to grow free cash flow by -5.4 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.4 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 4148 use?
Our models discount All Cosmos Bio-Tech Holding Corp at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For All Cosmos Bio-Tech Holding Corp that is -5.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has All Cosmos Bio-Tech Holding Corp (4148) delivered so far?
Over the past 5 years revenue at All Cosmos Bio-Tech Holding Corp grew +12.4 % a year. The price currently implies free-cash-flow growth of -5.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of All Cosmos Bio-Tech Holding Corp (4148) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into All Cosmos Bio-Tech Holding Corp (-5.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of All Cosmos Bio-Tech Holding Corp (4148)?
The free-cash-flow yield on the price is 8.83 %: that much free cash flow All Cosmos Bio-Tech Holding Corp produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of All Cosmos Bio-Tech Holding Corp (4148)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For All Cosmos Bio-Tech Holding Corp it is 36.41 TWD per share (as of Nov 9, 2026), against a price of 28.80 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is All Cosmos Bio-Tech Holding Corp stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 4148 trades below its calculated fair value: price 28.80 TWD, fair value 36.41 TWD, a gap of about +26% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4148?
No. The price is what the market pays today (28.80 TWD); the fair value is what the company's own numbers justify (36.41 TWD). For All Cosmos Bio-Tech Holding Corp the two are 7.61 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is All Cosmos Bio-Tech Holding Corp worth?
The market values All Cosmos Bio-Tech Holding Corp at about 2.4B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 28.80 TWD; our models calculate a fair value of 36.41 TWD per share.
What do the bullish and bearish scenarios say about 4148?
Our models span a range for All Cosmos Bio-Tech Holding Corp: cautious scenario 30.84 TWD, base 36.41 TWD, optimistic 44.58 TWD per share (as of Nov 9, 2026, price 28.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4148?
All Cosmos Bio-Tech Holding Corp trades at a price-to-earnings ratio of 10.4 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 36.41 TWD is built from several models across several years. Other multiples: P/B 0.9, P/S 1.0, EV/EBITDA 4.5.
How solid is the balance sheet of All Cosmos Bio-Tech Holding Corp (4148)?
Balance-sheet figures for All Cosmos Bio-Tech Holding Corp (as of Nov 9, 2026): return on equity 7.6%, debt of 0.05 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 4148 from its 52-week high?
All Cosmos Bio-Tech Holding Corp trades at 28.80 TWD, about 34% below its 52-week high of 43.60 TWD and 3% above the low of 28.05 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 36.41 TWD is for.
Which stocks are comparable to All Cosmos Bio-Tech Holding Corp?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is All Cosmos Bio-Tech Holding Corp stock attractive at the current price?
The data as of Nov 9, 2026: price 28.80 TWD, calculated fair value 36.41 TWD (+26%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4148 calculated?
We run All Cosmos Bio-Tech Holding Corp through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 36.41 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. All Cosmos Bio-Tech Holding Corp currently trades 21% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of All Cosmos Bio-Tech Holding Corp (4148)?
The closing price on Nov 9, 2026 was 28.80 TWD. Our model-based fair value is 36.41 TWD, about +26% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with All Cosmos Bio-Tech Holding Corp right now?
The price is below even our cautious bear case (30.84 TWD). The market is more pessimistic than our downside scenario. Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of All Cosmos Bio-Tech Holding Corp (4148) come from?
Earnings per share at All Cosmos Bio-Tech Holding Corp grew −7.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share −0.9 %, EBIT margin −5.1 %, tax rate −4.0 %, residual (interest, one-offs) +2.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of All Cosmos Bio-Tech Holding Corp
How large is the market capitalisation of All Cosmos Bio-Tech Holding Corp (4148)?
The market capitalisation of All Cosmos Bio-Tech Holding Corp is 2.4B TWD (≈ $72.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of All Cosmos Bio-Tech Holding Corp (4148)?
The price-to-sales ratio of All Cosmos Bio-Tech Holding Corp is 0.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of All Cosmos Bio-Tech Holding Corp (4148)?
Earnings per share at All Cosmos Bio-Tech Holding Corp are 2.76 TWD (price ÷ EPS = P/E 10.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of All Cosmos Bio-Tech Holding Corp (4148)?
The dividend yield of All Cosmos Bio-Tech Holding Corp is 3.5% (payout 36.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of All Cosmos Bio-Tech Holding Corp (4148)?
The net margin of All Cosmos Bio-Tech Holding Corp is 5.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of All Cosmos Bio-Tech Holding Corp (4148)?
The return on equity (ROE) of All Cosmos Bio-Tech Holding Corp is 7.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of All Cosmos Bio-Tech Holding Corp (4148)?
On an EBIT basis the return on assets of All Cosmos Bio-Tech Holding Corp is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of All Cosmos Bio-Tech Holding Corp (4148)?
The operating margin of All Cosmos Bio-Tech Holding Corp is 12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at All Cosmos Bio-Tech Holding Corp (4148)?
Revenue at All Cosmos Bio-Tech Holding Corp is growing +33.1% versus a year earlier (3y avg −7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at All Cosmos Bio-Tech Holding Corp (4148)?
Earnings per share at All Cosmos Bio-Tech Holding Corp are growing +114% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does All Cosmos Bio-Tech Holding Corp (4148) hold?
All Cosmos Bio-Tech Holding Corp holds more cash than debt, 843M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch All Cosmos Bio-Tech Holding Corp in the live analysis
One click puts All Cosmos Bio-Tech Holding Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026